EUCTR2006-002532-24-GB进行中（未招募）1 期
Pharmacogenetic study of Fc?RIIIa and HER2 genes in relation to treatment of breast cancer - HER2 PG study
ewcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 750 人开始时间: 2007年4月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Aged 18 years or over.
- •b) Histological confirmation of primary breast cancer with HER2 testing.
- •c) Written voluntary informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a) Under the age of 18 years.
- •b) Unable to give informed consent.
研究者
相似试验
已完成
2 期
Cetuximab and Lenalidomide in Head and NeckSquamous Cell CarcinomaNCT01133665University of Chicago42
已完成
不适用
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's MacroglobulinemiaWaldenstrom's MacroglobulinemiaNCT00142155Dana-Farber Cancer Institute300
已完成
2 期
Pharmacogenomic analysis for Phase II clinical trial of the third-line Cetuximab and irinotecan or Cetuximab therapy for patients with KRAS wild type unresectable/recurrent colorectal cancerColorectal CancerJPRN-UMIN000004507ational Cancer Center Hospital60
招募中
不适用
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast CancerHER2-positive Breast CancerNCT06722612Shu Wang2,916
尚未招募
Unknown
Effect of genetic profile on hemodynamic changes following etomidate induction.CTRI/2024/05/067100Maulana Azad medical college and associated Lok Nayak hospital